AI-generated summary
The authors report a randomized, double-masked, sham-controlled trial of red-light photobiomodulation applied over closed eyelids in patients with dry eye disease linked to thyroid eye disease that persisted despite standard treatment. Compared with sham, the treatment group had lower Ocular Surface Disease Index scores through two months after treatment and lower tear osmolarity, with no treatment-related adverse events reported. The study has a small sample, and several secondary outcomes showed no clear between-group difference.
- Participants
- 46
- Who or what was studied
- Eyes of patients with thyroid eye disease-associated dry eye disease that remained symptomatic despite maximal conservative therapy
- Wavelengths
- 630 nm
- Limits stated in the abstract
- Small sample (46 eyes), with several secondary outcomes showing no multiplicity-adjusted between-group differences and some findings based on exploratory analyses.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on mdpi.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Sham, Low-level laser therapy, Dry eye, GRADE, Light-emitting diode, Photobiomodulation, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.